

ACHILLION PHARMACEUTICALS INC

Form 8-K

March 24, 2015

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2015

Achillion Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

001-33095
(Commission

File Number)

52-2113479
(IRS Employer

Identification No.)

300 George Street

06511

New Haven, CT

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (203) 624-7000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14a-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On March 18, 2015, Dr. Gautam Shah, the Executive Vice President and Chief Regulatory Officer of Achillion Pharmaceuticals, Inc. (the Company), provided notice of his departure from the Company effective March 31, 2015. Subject to Dr. Shah executing a release of all claims against the Company and its affiliates, Dr. Shah will be entitled to receive benefits pursuant to the terms of his employment agreement dated April 5, 2011. Dr. Shah will continue to be subject to the terms of a Non-Competition and Non-Solicitation Agreement and a Non-Disclosure and Assignment of Inventions Agreement previously entered into with the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACHILLION PHARMACEUTICALS, INC.

Date: March 24, 2015

By: /s/ Mary Kay Fenton

Mary Kay Fenton

Executive Vice President and Chief Financial
Officer